The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis
Open accessAbstract
// Liangyou Gu 1, * , Hongzhao Li 1, * , Luyao Chen 1, * , Xin Ma 1 , Xintao Li 1 , Yu Gao 1 , Yu Zhang 1 , Yongpeng Xie 1, 2 , Xu Zhang 1 1 Department of Urology/State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/PLA Medical School, Beijing, China 2 School of Medicine, Nankai University, Tianjin, China * These authors contributed equally to this work Correspondence to: Xu Zhang, e-mail: xzhang@foxmail.com Keywords: inflammation, lymphocyte to monocyte ratio, cancer, prognosis, meta-analysis Received: August 30, 2015 Accepted: February 10, 2016 Published: March 03, 2016 ABSTRACT Inflammation influences cancer development and progression, and a low lymphocyte to monocyte ratio (LMR) has been reported to be a poor prognostic indicator in several malignancies. Here we quantify the prognostic impact of this biomarker and assess its consistency in various cancers. Eligible studies were retrieved from PubMed, Embase and Web of Science databases. Overall survival (OS) was the primary outcome, cancer-specific survival (CSS), disease-free survival (DFS), recurrence-free survival (RFS), and progression-free survival (PFS) were secondary outcomes. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated. Fifty-six studies comprising 20,248 patients were included in the analysis. Overall, decreased LMR was significantly associated with shorter OS in non-hematological malignancy (HR: 0.59, 95% CI: 0.53–0.66; P < 0.001) and hematological malignancy (HR: 0.44, 95% CI: 0.34–0.56; P < 0.001). Similar results were found in CSS, DFS, RFS and PFS. Moreover, low LMR was significantly associated with some clinicopathological characteristics that are indicative of poor prognosis and disease aggressiveness. By these results, we conclude that a decreased LMR implied poor prognosis in patients with cancer and could serve as a readily available and inexpensive biomarker for clinical decision.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Bingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022
Trophic macrophages in development and disease
Pollard, J. W. (2009) · Nature Reviews Immunology · doi:10.1038/nri2528 · Cited by 1,178
Macrophages Regulate the Angiogenic Switch in a Mouse Model of Breast Cancer
Lin, E. Y., Li, J.-F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D. A., Qian, H., Xue, X.-N., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1278 · Cited by 1,074
Cited by
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 840
Cespedes Feliciano, E. M., Kroenke, C. H., Meyerhardt, J. A., Prado, C. M., Bradshaw, P. T., Kwan, M. L., Xiao, J., Alexeeff, S., Corley, D., Weltzien, E., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2319 · Cited by 427
Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs
Brady, R. V., & Thamm, D. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1176807 · Cited by 35
Salman, E., Çelikbilek, N., Aydoğan, S., Özdem, B., Gökay, S., Kırca, F., Toyran, A., Bilici Salman, R., & Dinç, B. (2021) · Mikrobiyoloji Bulteni · doi:10.5578/mb.20219706 · Cited by 15
Metadata
- Authors
- Gu, L., Li, H., Chen, L., Ma, X., Li, X., Gao, Y., Zhang, Y., Xie, Y., & Zhang, X.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-03-03
- Volume
- 7
- Issue
- 22
- Pages
- 31926-31942
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2292094308
- Cited by
- 178
- References
- 4
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. https://app.cochat.ai/papers/10.18632/oncotarget.7876
- The paper
- Gu, L., Li, H., Chen, L., Ma, X., Li, X., Gao, Y., Zhang, Y., Xie, Y., & Zhang, X. (2016). Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget. https://doi.org/10.18632/oncotarget.7876
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.